Hochstrasser K, Gebhard W, Albrecht G, Rasp G, Kastenbauer E
Department of Otorhinolaryngology, Ludwig Maximilians University, Munich, Federal Republic of Germany.
Eur Arch Otorhinolaryngol. 1993;249(8):455-8. doi: 10.1007/BF00168853.
Mast cell degranulation results in the release of serine class proteinases with trypsin- and chymotrypsin-like specificity. While looking for natural protein inhibitors of these enzymes, we studied their reactions with the double-headed Kunitz-type inhibitor, bikunin, and the human bronchial secretion inhibitor (BSI), which are the only known low-molecular-mass proteinase inhibitors of the human respiratory tract. Both trypsin and chymotrypsin can be inhibited by these inhibitors. However, human BSI is unable to inhibit human tryptase and is the physiological counterpart of chymase in the upper respiratory tract. Human bikunin is unable to inhibit human chymase and human tryptase. Furthermore, human tryptase is also not inhibited by a fragment that consists only of the trypsin-specific C-terminal inhibitor domain of human bikunin. This finding contradicts reports that claim the occurrence of a tryptase-specific proteinase inhibitor in rat mast cells.
肥大细胞脱颗粒导致具有胰蛋白酶样和糜蛋白酶样特异性的丝氨酸类蛋白酶释放。在寻找这些酶的天然蛋白质抑制剂时,我们研究了它们与双头库尼茨型抑制剂比库宁以及人支气管分泌抑制剂(BSI)的反应,这两种是人类呼吸道中仅知的低分子量蛋白酶抑制剂。胰蛋白酶和糜蛋白酶都能被这些抑制剂抑制。然而,人BSI无法抑制人组织蛋白酶,并且是上呼吸道中糜酶的生理对应物。人比库宁无法抑制人糜酶和人组织蛋白酶。此外,仅由人比库宁的胰蛋白酶特异性C末端抑制剂结构域组成的片段也不能抑制人组织蛋白酶。这一发现与声称在大鼠肥大细胞中存在组织蛋白酶特异性蛋白酶抑制剂的报道相矛盾。